BIOX

Bioceres Crop SolutionsA

Nasdaq / Materials

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

15%

Probability

Target price

$0.90

+83.5% vs current

Most likely

Base case

45%

Probability

Target price

$0.40

-18.5% vs current

B-

Bear case

40%

Probability

Target price

$0.14

-71.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-29

AI commentary

Low-coverage monitoring view. The company press release confirms a weak fiscal 3Q26 print and continuing liability-management work, while the current tape around $0.43 shows no clear rerating from distress. The packet does not include verified analyst revisions or a reliable post-print reaction read, so conviction stays low and the setup remains primarily a balance-sheet/watchlist story.

RankAlpha Sentiment Codex - 2026-05-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-11catalyst3Q26 print showed another weak revenue and margin step-downHigh impact

The company reported 3Q26 total revenue of $39.4 million, down 23% year over year, with net loss of $10.0 million and Adjusted EBITDA of $(0.6) million. The weakness came from softer Crop Protection demand, the ongoing Seeds transition, and a non-recurring inoculants obsolescence adjustment in Crop Nutrition [#PR-20260511].

2026-06-30eventLiability-management and refinancing work remains the key balance-sheet eventHigh impact

Management said it is still advancing liability-management initiatives, including debt reprofiling and a voluntary bond maturity extension process in Argentina, after the Pro Farm foreclosure auction and related noteholder dispute [#PR-20260511].

2026-12-31catalystCrop Nutrition growth and cost discipline could help stabilize the core businessHigh impact

Crop Nutrition revenue rose 15% year over year and SG&A fell 16%, showing that some operating levers are still working. If management continues to simplify the organization and improve working-capital execution, BIOX could eventually rerate off distressed levels, but this is a slow-burn thesis rather than a near-term recovery case [#PR-20260511].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-29 • Updated nightlySource: Internal modelMethodology